A novel rFab’ anti-PD-L1 reduces HNSCC proliferation, migration and invasion and potentiates the cisplatin effect suggesting its potential to be conjugated with drugs for immuno-cytotoxic therapy. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.